Xceleron and Organon sign microdose study agreement
UK company Xceleron has signed a collaboration agreement with Organon, the human healthcare business unit of Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development.
UK company Xceleron has signed a collaboration agreement with Organon, the human healthcare business unit of Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development.
Xceleron, a leader in human microdosing, was selected by Organon on the basis of fast and cost-effective delivery of human information that will enable it to make better choices in early drug development.
The three selected drug candidates are all compounds that have emerged from Organon's extensive gynaecological r&d activities. The purpose of the human microdose study is to quickly assess all-important pharmacokinetic properties of the compounds while confirming the scalability of the microdose to pharmacological dose for these compounds.
Xceleron will use its ultra-sensitive Accelerator Mass Spectrometry analytical technology to determine human plasma concentrations after microgram administration of the various drug candidates.
"We have commissioned this microdose study to examine important pharmacokinetic parameters in humans to aid confirmation of the best candidate for further development," said David Nicholson, executive vice-president research & development of Organon. "The most compelling reason for using human microdosing is the speed with which we can gain results from human studies to make pivotal decisions."
